权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Endoplasmic Reticulum-to-Mitochondria Calcium Transfer in Pancreatic Cancer Development, Metastasis, and Treatment

胰腺癌发生、转移和治疗中的内质网至线粒体钙转移

基本信息

批准号：
10443604
负责人：
James Kevin FOSKETT
金额：
$ 51.61万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10443604
关键词：
Ablation Acute American Animal Model Animals Autophagocytosis Biochemical Bioenergetics Biological Biological Assay Biophysics CRISPR/Cas technology Calcium Cancer Patient Cancer cell line Cause of Death Cell Culture Techniques Cell Line Cell Survival Cells Cellular Metabolic Process Cessation of life Citric Acid Cycle Cytoplasm Dependence Development Diagnosis Disease Early Diagnosis Early identification Electrophysiology (science)Endoplasmic Reticulum Fibroblasts Future Gel Genetic Genetic Models Growth Homeostasis Human ITPR1 gene Immune response In Vitro Interruption Invaded Ion Channel Lead Luciferases Maintenance Malignant Neoplasms Malignant neoplasm of pancreas Malignant neoplasm of prostate Mediating Membrane Metabolic Metabolism Methods Mitochondria Modeling Molecular Morphology Mus NOD/SCID mouse Neoplasm Metastasis Normal Cell Organelles Oxidoreductase Oxygen Consumption Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pathway interactions Patient-Focused Outcomes Patients Permeability Pharmaceutical Preparations Pharmacology Play Process Prognosis Property Proteins Regulation Renal carcinoma Reporter Genes Role Savings Signal Transduction Site Survival Rate System Tail Technology Therapeutic Veins Work advanced disease anti-cancer anti-cancer therapeutic biophysical techniques calcium uniporter cancer cell cancer therapy cell motility cell type designer receptors exclusively activated by designer drugs epithelial to mesenchymal transition falls genetic predictors genetically modified cells improved in vivo innovation live cell imaging malignant breast neoplasm migration mouse model neoplastic cell new therapeutic target novel novel therapeutics pancreatic cancer patients pancreatic cell line response targeted treatment therapeutic target three-dimensional modeling tumor tumor progression tumorigenesis tumorigenic uptake

项目摘要

Pancreatic adenocarcinoma (PDAC) is a particularly lethal form of cancer that kills over 40,000 Americans every year. PDAC is most often diagnosed when disease is advanced, with metastases that lead to death. Patient outcomes are further negatively-impacted by a typical poor response to currently-available treatments. It is thus critical to develop a stronger understanding of the processes which lead to PDAC development and metastasis, as well as to determine novel, more-efficacious targets for therapies. Low-level, constitutive endoplasmic reticulum (ER)-to-mitochondria transfer of calcium is required for optimal bioenergetics and cancer-cell survival. We hypothesize that this pathway contributes to pancreatic cancer development, metastasis, and tumor maintenance, and may therefore present a viable anticancer target. The ER-localized IP3R calcium-release ion channel and the mitochondrial calcium-uniporter ion channel, MCU, mediate calcium transfer between the two organelles at membrane-contact sites. However, it has been impossible to target this pathway in vivo because of the lack of selective, cell-permeable pharmacological agents against these ion channels. We therefore propose to examine the role of ER-to-mitochondria calcium transfer in PDAC development, metastasis, and tumor maintenance through the use of novel animal and cell-culture models. We will genetically delete MCU during early development in a murine genetic-model of PDAC, the KPCY mouse, to observe the role of this protein in tumor development. In addition, we will use tumor cells as well as genetically- modified cells using Cre/lox and CRISPR/Cas9 systems, as well as patient-derived cell lines and the established human PDAC cell line, Panc-1. We will assay proliferation, cellular bioenergetics, oxygen consumption rates, and mitochondrial calcium homeostasis, using biochemical, cell biological and biophysical approaches, including electrophysiology, live-cell imaging and fluorimetry, to define the role of ER-to- mitochondria calcium transfer in these processes. To determine the role of MCU in metastasis, we will quantify metastasis in the KPCY model using the sensitive YFP-reporter gene, and we will use an in vivo tail-vein metastasis model with genetically-modified Panc-1 cells expressing luciferase in NOD/SCID mice, as well as in vitro transwell-invasion and gel-degradation assays, and biochemical and morphological assessment of metastasis-associated markers of epithelial-to-mesenchymal transition. To observe the role of ER-to- mitochondria calcium transfer in tumor maintenance and thus its therapeutic potential for more advanced disease, we will use an inducible CRISPR/Cas9 cell-culture model of murine PDAC in vitro and an in vivo inducible orthotopic model to observe the effects of acute MCU ablation in already-growing tumors and cells as a method to simulate profound pharmacological inhibition. These studies will elucidate the role of ER-to- mitochondria calcium transfer in PDAC development, metastasis, and maintenance, and they may inform future development of novel therapeutic targets in PDAC, potentially saving lives.

胰腺腺癌（PDAC）是一种特别致命的癌症，导致超过4万美国人死亡